Vertex Pharmaceuticals Inc. faced the music on Incivek (telaprevir), slashing 370 jobs – 15 percent of its work force – after patients turned from the flagging hepatitis C virus (HCV) drug to newer therapies. Revenues from Incivek plummeted to $85.6 million in the third quarter from $254.3 million during the same period a year earlier.